Risultati per: Linee guida NICE sul dolore primario cronico
Questo è quello che abbiamo trovato per te
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barretts oesophagus and stage I oesophageal adenocarcinoma
Barrett’s oesophagus is the only known precursor to oesophageal adenocarcinoma, a cancer with very poor prognosis. The main risk factors for Barrett’s oesophagus are a history of gastro-oesophageal acid reflux symptoms and obesity. Men, smokers and those with a family history are also at increased risk. Progression from Barrett’s oesophagus to cancer occurs via an intermediate stage, known as dysplasia. However, dysplasia and early cancer usually develop without any clinical signs, often in individuals whose symptoms are well controlled by acid suppressant medications; therefore, endoscopic surveillance is recommended to allow for early diagnosis and timely clinical intervention. Individuals with Barrett’s oesophagus need to be fully informed about the implications of this diagnosis and the benefits and risks of monitoring strategies. Pharmacological treatments are recommended for control of symptoms, but not for chemoprevention. Dysplasia and stage 1 oesophageal adenocarcinoma have excellent prognoses, since they can be cured with endoscopic or surgical therapies. Endoscopic resection is the most accurate staging technique for early Barrett’s-related oesophageal adenocarcinoma. Endoscopic ablation is effective and indicated to eradicate Barrett’s oesophagus in patients with dysplasia. Future research should focus on improved accuracy for dysplasia detection via new technologies and providing more robust evidence to support pathways for follow-up and treatment.
Linea guida sulla cardiomiopatia ipertrofica
Diagnosi e trattamento della vescica iperattiva idiopatica: linea guida
Assistenza di sopravvivenza per persone affette da cancro avanzato o metastatico: linea guida
Perdita dell’udito legata all’età: linea guida
ACP: linee guida cliniche per i nuovi trattamenti del diabete tipo 2
Dolore cronico,ne soffre 1 miliardo e mezzo di persone nel mondo
Esperta,studi su molecola contro perdita efficacia dei farmaci
Dolore cronico,ne soffre 1 miliardo e mezzo di persone nel mondo
Esperta,studi su molecola che contrasta perdita efficacia farmac